The Global Central Precocious Puberty Market, by Drug (Leuprolide Acetate, Triptorelin, Histrelin Acetate, and Nafarelin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 1,595.2 million in 2022 and expected to exhibit a CAGR of 7.9% during the forecast period (2022-2030).
The high efficiency of triptorelin in treating central precocious puberty (CPP) is anticipated to drive the market growth over the forecast period. For instance, according to the data published in the Journal of Pediatric Endocrinology and Metabolism in February 2017, the administration of triptorelin with 6-month formulation was found to be safe and effective in suppressing pituitary-gonadal axis in children with CPP. Furthermore, an extended injection interval may improve compliance in the management of CPP.
Global Central Precocious Puberty Market - Impact of Coronavirus (COVID-19) Pandemic
Supply chain and manufacturing activities in India, Italy, Spain, the U.K., and the U.S. have been disrupted due to lockdowns implemented by governments in the during the pandemic, while countries such as Saudi Arabia, UAE, Egypt, and others are facing problems with regard to transportation of raw materials, chemicals, and finished products.
The coronavirus or COVID-19 outbreak that started from Wuhan, China has spread across continents, affecting various industries globally. The supply of key materials has been severely disrupted due to forced quarantine and lack of labor and raw materials. As the link between regional warehouses is not smooth, the transportation of raw materials between regions cannot be carried out successfully. This shortage of raw materials and components has thus affected the supply chain of the global central precocious puberty market.
Browse 33 Market Data Tables and 25 Figures spread through 167 Pages and in-depth TOC on Global Central Precocious Puberty Market, by Drug (Leuprolide Acetate, Triptorelin, Histrelin Acetate, and Nafarelin), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
To know the latest trends and insights prevalent in the global central precocious puberty market, click the link below:
https://www.coherentmarketinsights.com/market-insight/central-precocious-puberty-market-4960
Increasing initiatives taken by market players in order to spread awareness about central precocious puberty are expected to propel the market growth over the forecast. For instance, in February 2021, Tolmar Pharmaceuticals, Inc., a specialty pharmaceutical company, announced the launch of a newly established community and guide for caregivers who have children with central precocious puberty (CPP), "Little a Little Longer”. The member of the "Little a Little Longer" community will receive monthly updates including stories from other caregivers, insights from doctors, and tools to connect members of the central precocious puberty (CPP) community.
Key Takeaways of the Global Central Precocious Puberty Market:
- The global central precocious puberty market is expected to exhibit a CAGR of 7.9% over the forecast period (2022-2030). North America is expected to account for a major market share over the forecast period, owing to the increasing introduction of reimbursement policies for the treatment of central precocious puberty in the U.S. For instance, in May 2021, the Centers for Medicare and Medicaid Services (CMS) assigned a new product-specific billing code, J1951, to identify FENSOLVI (leuprolide acetate) for injectable suspension, indicated for the treatment of pediatric patients aged two years and older with central precocious puberty (CPP). The new J-code became effective on July 1, 2021.
- Some of the major players operating in the global central precocious puberty market include Teva Pharmaceutical Industries Ltd., AbbVie Inc., Arbor Pharmaceuticals, LLC, Pfizer Inc., Tolmar Pharmaceuticals, Inc., Endo International plc, Ipsen Pharma, Debiopharm Group, and Sun Pharmaceutical Industries Limited
